RaQualia Pharma Past Earnings Performance
Past criteria checks 0/6
RaQualia Pharma has been growing earnings at an average annual rate of 57.8%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 22.3% per year.
Key information
57.8%
Earnings growth rate
58.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | 22.3% |
| Return on equity | -5.3% |
| Net Margin | -17.0% |
| Next Earnings Update | 15 May 2024 |
Revenue & Expenses BreakdownBeta
How RaQualia Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,901 | -323 | 860 | 1,372 |
| 30 Sep 23 | 2,509 | 139 | 882 | 1,342 |
| 30 Jun 23 | 2,485 | 279 | 846 | 1,323 |
| 31 Mar 23 | 2,949 | 695 | 806 | 1,253 |
| 31 Dec 22 | 2,918 | 723 | 797 | 1,248 |
| 30 Sep 22 | 3,057 | 1,053 | 864 | 1,187 |
| 30 Jun 22 | 2,903 | 922 | 865 | 1,159 |
| 31 Mar 22 | 2,460 | 447 | 868 | 1,135 |
| 31 Dec 21 | 2,776 | 755 | 936 | 1,127 |
| 30 Sep 21 | 2,157 | 261 | 721 | 1,037 |
| 30 Jun 21 | 2,055 | 155 | 722 | 978 |
| 31 Mar 21 | 1,639 | -90 | 718 | 964 |
| 31 Dec 20 | 1,107 | -606 | 656 | 932 |
| 30 Sep 20 | 1,567 | -162 | 814 | 901 |
| 30 Jun 20 | 1,529 | -144 | 831 | 884 |
| 31 Mar 20 | 1,478 | -221 | 844 | 878 |
| 31 Dec 19 | 1,702 | 5 | 850 | 864 |
| 30 Sep 19 | 920 | -791 | 676 | 900 |
| 30 Jun 19 | 844 | -818 | 658 | 901 |
| 31 Mar 19 | 695 | -895 | 661 | 897 |
| 31 Dec 18 | 744 | -1,104 | 738 | 1,074 |
| 30 Sep 18 | 1,345 | -439 | 770 | 1,074 |
| 30 Jun 18 | 1,401 | -367 | 780 | 1,058 |
| 31 Mar 18 | 1,398 | -304 | 778 | 1,037 |
| 31 Dec 17 | 1,419 | -58 | 713 | 848 |
| 30 Sep 15 | 93 | -2,154 | 758 | 1,537 |
| 30 Jun 15 | 103 | -2,021 | 777 | 1,465 |
| 31 Mar 15 | 143 | -2,033 | 787 | 1,477 |
| 31 Dec 14 | 153 | -638 | 822 | 1,515 |
| 30 Sep 14 | 230 | 338 | 828 | 1,394 |
| 30 Jun 14 | 241 | 256 | 850 | 1,390 |
| 31 Mar 14 | 221 | 432 | 866 | 1,479 |
| 31 Dec 13 | 228 | -1,108 | 848 | 1,518 |
Quality Earnings: 4579 is currently unprofitable.
Growing Profit Margin: 4579 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4579 is unprofitable, but has reduced losses over the past 5 years at a rate of 57.8% per year.
Accelerating Growth: Unable to compare 4579's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4579 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (0.6%).
Return on Equity
High ROE: 4579 has a negative Return on Equity (-5.28%), as it is currently unprofitable.